EGFR and metastatic colorectal cancer: Genotyping of oncogenic RAS mutations is routinely undertaken as it is an important biomarker used to predict drug resistance to epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies in patients with metastatic colorectal cancer (mCRC) [1, 2, 3].